Iron deficiency occurs frequently in patients with chronic heart failure and is associated with an increased risk of heart transplantation. Chronic inflammatory processes are often the main cause for impaired iron metabolism.
The new European Society of Cardiology Heart Failure Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure1, published in May 2012 recognise, for the first time, iron deficiency as a co-morbidity of heart failure (HF) and include evidence from the FAIR-HF study2, demonstrating the benefit of ferric carboxymaltose in chronic heart failure patients with iron deficiency.
More details available on the ESC website.
1. McMurray JJ, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–1847
2. Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448